Q-omics provides the consensus-scored SPAG16-DT profile across patient tissues and cancer cell-line models. SPAG16-DT expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SPAG16-DT is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, SPAG16-DT RNA expression shows 16,533 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KICH, and THYM as cancer lineages where SPAG16-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPAG16-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPAG16-DT survival associations across molecular data types. SPAG16-DT RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPAG16-DT RNA expression–survival associations across cancer types. High SPAG16-DT expression shows unfavorable associations in ACC and UCEC, but favorable associations in UVM, SKCM, PAAD and UCS. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SPAG16-DT RNA expression.
This table summarizes SPAG16-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SPAG16-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPAG16-DT shows lower tumor expression in KICH, KIRC, COAD, UCEC and LUSC and higher tumor expression in STAD. The KICH box plot shows higher SPAG16-DT RNA expression in normal versus tumor tissue (log2 FC = −0.472, t-test p < 0.001).
This table shows molecular features associated with SPAG16-DT in patient tissues and cancer cell lines. In patient samples, SPAG16-DT shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
